SCHEMBL21641320

SCHEMBL21641320

CCCOc1cc(N)nn1C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 6/20 0.39
ABL1 P00519 4/20 0.39
HCK P08631 2/20 0.39
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PDE2A O00408 1/20 0.35
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
KDM4E B2RXH2 3/20 0.33
TP53 P04637 2/20 0.33
GAA P10253 2/20 0.33
MPO P05164 2/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
POLB P06746 1/20 0.33
CASP1 P29466 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21639872 0.77 MAPT (0.36) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL8378995 0.77 SRC (0.38) SRCABL1HCKMPOEGFR
SCHEMBL21641026 0.75 HTR2C (0.46) SRCABL1RAB9AALDH1A1MAPT
SCHEMBL8373896 0.69 RET (0.34) PDE1APDE1BPDE1CMPO
SCHEMBL1001920 0.67 DGAT1 (0.34) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL2817008 0.66 PIK3CG (0.38) SRCABL1HCKSMN1; SMN2POLB
SCHEMBL25033914 0.64 ADORA3 (0.43) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL25247974 0.63 TGFBR1 (0.41) ALDH1A1KDM4EKMT2AL3MBTL1
SCHEMBL21640750 0.62 PLAU (0.34) ALDH1A1MPOMEN1POLBKMT2A
SCHEMBL21503677 0.61 MAP3K12 (0.42) ALDH1A1KDM4EGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3604305-B1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMA CO LTD (JP) 2024-08-28 EP disclosed
CN-110520422-B Novel pyridonecarboxylic acid derivative or salt thereof 涌永制药株式会社 2023-09-05 CN disclosed
US-11286255-B2 Pyridone carboxylic acid derivative or salt thereof WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2022-03-29 US disclosed
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2020-02-27 US disclosed
EP-3604305-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF Wakunaga Pharmaceutical Co., Ltd. (JP) 2020-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF RAB10, HDAC10, NEK10 SRC 1539/4885ABL1 924/4885HCK 797/4885
US-11286255-B2 Pyridone carboxylic acid derivative or salt thereof RARA, RAB10, RABL6 SRC 1507/4885ABL1 629/4885HCK 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.